Enzyme Composition Preventing Triglyceride Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The metabolic syndrome, characterized by excessive triglyceride reformation in the intestine, leads to obesity, type II diabetes, and cardiovascular diseases due to inefficient energy utilization from dietary fatty acids, as the body stores triglycerides rather than metabolizing them, causing metabolic imbalances and health complications.
Innovation Solution
A combination of proteolytic enzymes, such as subtilisin or nagarse, and lipolytic enzymes, like Cal A or Cal B lipases from Candida antarctica, Geotrichum candidum, or Candida rugosa, is used to inhibit the reformation of triglycerides in the intestine by breaking down 2-monoacylglycerol, disrupting the activity of enzymes involved in triglyceride synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Use of energy by moving object
If lipases break down triglycerides into free fatty acids and 2-monoacylglycerol for assimilation, then fatty acids become available for energy metabolism, but the body re-synthesizes triglycerides in intestinal epithelial cells leading to storage instead of energy utilization
Solution Approach 1:
The proteolytic enzyme acts preliminarily to degrade the synthetase enzyme before triglyceride re-synthesis can occur. By pre-emptively destroying the synthetic machinery in intestinal cells, the body is forced to utilize free fatty acids for energy rather than storing them, thus resolving the contradiction between energy availability and energy storage
Solution Approach 2:
The invention extracts and removes the synthetase enzyme from the intestinal epithelial cells using proteolytic digestion. By taking out this critical enzyme required for triglyceride re-synthesis, the system prevents the harmful storage pathway while maintaining the beneficial breakdown pathway, thereby improving energy utilization
2Quantity of substance
If the body re-synthesizes triglycerides in intestinal epithelial cells, then fatty acids are stored for future use, but this leads to obesity, type II diabetes, and cardiovascular diseases due to metabolic syndrome
Solution Approach 1:
The invention converts the harmful re-synthesis process into a beneficial energy utilization process. By using proteolytic enzymes to selectively degrade synthetase in intestinal cells (harmful action on the wrong target), we inadvertently prevent triglyceride storage and force the body to burn fatty acids for energy (beneficial outcome), thus converting a potential harm into a therapeutic benefit
Solution Approach 2:
The proteolytic enzyme acts as an intermediary agent that mediates between the breakdown products (free fatty acids and 2-monoacylglycerol) and the re-synthesis pathway. By introducing this intermediary that selectively destroys the synthetase enzyme, the system redirects metabolic flow from storage to energy utilization, preventing metabolic syndrome
3Productivity
If proteolytic enzymes are used to degrade synthetase and prevent triglyceride re-synthesis, then triglyceride levels in blood are reduced and energy utilization improves, but the mechanism involves complex enzymatic interactions in intestinal epithelial cells
Solution Approach 1:
The invention segments the metabolic process into distinct locations and functions: lipases act in the lumen to break down triglycerides, while proteolytic enzymes act within intestinal cells to degrade synthetase. This spatial segmentation allows each enzyme to perform its specific function without interference, simplifying the overall mechanism despite the complexity of cellular processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively prevents the resynthesis of triglycerides, reducing triglyceride levels in the blood, thereby aiding in weight management and improving metabolic health by enhancing the bioavailability of fatty acids for energy utilization, thus addressing the metabolic deficiencies associated with obesity and related disorders.
Implementation Method 1
They must be broken down into diglycerides, monoglycerides, and free fatty acids, thanks to the action of lipases in the digestive tract
Implementation Method 2
The present invention relates to a composition comprising in combination at least one proteolytic enzyme and at least one lipolytic enzyme, for use in the prevention or treatment of obesity by preventing the synthesis of triglycerides, by degrading 2-monoacylglycerol in the intestine
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to a composition comprising a combination of at least one proteolytic enzyme, such as subtilisin, and at least one lipolytic enzyme, for use in preventing triglyceride synthesis, advantageously by degrading 2-monoacylglycerol in the intestine. The subject matter of the invention is also such a composition for use as a medicament, as a cosmetic agent, as a medical device, as a food composition, as a food supplement or else as a nutriceutical, in particular for use in preventing or treating obesity, atherosclerosis or type II diabetes, or else for use in preventing or reducing excess weight.